Inside Washington State's Legal Cannabis Market: THC Levels, Prices, and the Rise of Concentrates

Analysis of over 44 million legal cannabis purchases in Washington showed concentrates growing 146% in market share with triple the THC of flower, while consumers consistently paid more for higher-potency products.

Smart, Rosanna et al.·Addiction (Abingdon·2017·Strong EvidenceRetrospective Cohort
RTHC-01523Retrospective CohortStrong Evidence2017RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Retrospective Cohort
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Analyzing Washington State's cannabis traceability data from July 2014 to September 2016 (over 44 million purchases), the study revealed several market trends.

Traditional cannabis flower still dominated at 66.6% of spending, but extracts for inhalation (concentrates) grew by 145.8% in market share, reaching 21.2% of sales. The average THC level for extracts was 68.7%, more than triple that of flower (20.6%).

Consumers paid a premium for potency: for flower products, both THC (coefficient = 0.012) and CBD (coefficient = 0.017) were associated with statistically significant per-gram price increases. CBD commanded an even higher price premium than THC, despite CBD's much lower average concentrations in most products.

Quantity discounts were small but significant (elasticity = -0.06), meaning bulk buyers saved modestly per gram.

Key Numbers

44,482,176 total purchases analyzed. 31,052,123 flower purchases after trimming outliers. Flower: 66.6% of spending, average THC 20.6%. Extracts: grew to 21.2% of spending, average THC 68.7%. THC premium: $0.012/gram per percentage point. CBD premium: $0.017/gram per percentage point. Quantity discount elasticity: -0.06.

How They Did This

Secondary analysis of Washington State's mandatory cannabis traceability system data. Descriptive statistics assessed product trends and potency. Hedonic regressions estimated how THC, CBD, and purchase quantity influenced flower pricing across 31 million flower purchases.

Why This Research Matters

This is one of the most comprehensive analyses of a legal cannabis market ever conducted, covering over 44 million transactions. It provides hard data on what consumers actually buy, what they pay, and how the market is evolving. The rapid growth of high-potency concentrates is particularly relevant for public health, as these products deliver THC at levels far exceeding traditional flower.

The Bigger Picture

The data reveals a market trending toward higher potency. As extracts grow in market share and consumer willingness to pay more for higher THC drives product development, the average THC exposure per consumer is likely increasing. This has implications for public health research, which has largely studied lower-potency cannabis, and for regulatory approaches to potency limits.

What This Study Doesn't Tell Us

Washington State data may not represent other legal markets. The traceability system captures legal market transactions only; illegal market activity is not included. Product testing accuracy and consistency across labs is a known concern. The study period (2014-2016) covers the early years of legal sales, and the market has continued to evolve.

Questions This Raises

  • ?Should legal markets regulate maximum THC levels, especially for concentrates?
  • ?Does the consumer premium for CBD-rich products reflect therapeutic demand or marketing influence?
  • ?How does the shift toward concentrates affect health outcomes for regular users?

Trust & Context

Key Stat:
Concentrates averaged 68.7% THC versus 20.6% for flower, and grew 146% in market share
Evidence Grade:
Strong evidence from comprehensive analysis of a state-mandated traceability system covering over 44 million transactions.
Study Age:
Published in 2017, using 2014-2016 data. Washington's cannabis market has continued to evolve.
Original Title:
Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state.
Published In:
Addiction (Abingdon, England), 112(12), 2167-2177 (2017)
Database ID:
RTHC-01523

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-ControlFollows or compares groups over time
This study
Cross-Sectional / Observational
Case Report / Animal Study

Looks back at existing records to find patterns.

What do these levels mean? →

Frequently Asked Questions

How strong are cannabis concentrates compared to flower?

In Washington State's legal market, concentrates averaged 68.7% THC compared to 20.6% for flower, more than triple the potency. Some concentrates tested even higher. This potency difference is important to understand for dosing and health effects.

Do consumers pay more for stronger cannabis?

Yes. The study found statistically significant price premiums for both higher THC and higher CBD content. Interestingly, consumers paid a slightly larger premium for CBD ($0.017/gram per percentage point) than for THC ($0.012), suggesting demand for CBD-rich products.

Read More on RethinkTHC

Cite This Study

RTHC-01523·https://rethinkthc.com/research/RTHC-01523

APA

Smart, Rosanna; Caulkins, Jonathan P; Kilmer, Beau; Davenport, Steven; Midgette, Greg. (2017). Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state.. Addiction (Abingdon, England), 112(12), 2167-2177. https://doi.org/10.1111/add.13886

MLA

Smart, Rosanna, et al. "Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state.." Addiction (Abingdon, 2017. https://doi.org/10.1111/add.13886

RethinkTHC

RethinkTHC Research Database. "Variation in cannabis potency and prices in a newly legal ma..." RTHC-01523. Retrieved from https://rethinkthc.com/research/smart-2017-variation-in-cannabis-potency

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.